Scholarlink

Background <p>Pancreatic cancer is a highly aggressive malignancy characterized by limited treatment options, poor prognosis, and high mortality rates. nuclear activating miRNA (NamiRNA) enhances gene expression by interacting with nuclear enhancers, offering a novel avenue for understanding gene regulation in cancer. This study explores the dual role of mir-200c in regulating tumor proliferation and migration in pancreatic cancer, with the aim of identifying potential therapeutic strategies.</p> Results <p>Mir-200c significantly activated PTPN6 transcription via the NamiRNA-enhancer pathway, reducing tumor proliferation. Deletion of the enhancer sequence abolished the activation of PTPN6. Furthermore, mir-200c mediated the post-transcriptional repression of CDH17, impairing tumor migration. In vivo, LNP-enclosed mir-200c exhibited strong anti-tumor effects, further validating its therapeutic potential.</p> Conclusions <p>Mir-200c inhibits pancreatic cancer cell proliferation and migration through dual mechanisms: activation of PTPN6 transcription and repression of CDH17 expression. These findings suggest that mir-200c, particularly when delivered via LNP systems, may serve as a promising therapeutic strategy for pancreatic cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

LNP-enclosed NamiRNA inhibits pancreatic cancer proliferation and migration via dual pathways

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年7月3日

查看全文
  • Chao Yu,
  • Zhou Fang,
  • Qingyu Xie,
  • Zhuo Wu,
  • Peixian Huang,
  • Jinlong Yu,
  • Rufu Chen

摘要

Background

Pancreatic cancer is a highly aggressive malignancy characterized by limited treatment options, poor prognosis, and high mortality rates. nuclear activating miRNA (NamiRNA) enhances gene expression by interacting with nuclear enhancers, offering a novel avenue for understanding gene regulation in cancer. This study explores the dual role of mir-200c in regulating tumor proliferation and migration in pancreatic cancer, with the aim of identifying potential therapeutic strategies.

Results

Mir-200c significantly activated PTPN6 transcription via the NamiRNA-enhancer pathway, reducing tumor proliferation. Deletion of the enhancer sequence abolished the activation of PTPN6. Furthermore, mir-200c mediated the post-transcriptional repression of CDH17, impairing tumor migration. In vivo, LNP-enclosed mir-200c exhibited strong anti-tumor effects, further validating its therapeutic potential.

Conclusions

Mir-200c inhibits pancreatic cancer cell proliferation and migration through dual mechanisms: activation of PTPN6 transcription and repression of CDH17 expression. These findings suggest that mir-200c, particularly when delivered via LNP systems, may serve as a promising therapeutic strategy for pancreatic cancer.